109760-77-2

Basic information

• Product Name: D,L-ERYTHRO-1-PHENYL-2-DECANOYLAMINO-3-MORPHOLINO-1-PROPANOL HCL
• Synonyms: D,L-ERYTHRO-1-PHENYL-2-DECANOYLAMINO-3-MORPHOLINO-1-PROPANOL HCL;D,L-ERYTHRO-PDMP
• CAS NO: 109760-77-2
• Molecular Formula: C23H38N2O3.ClH
• Molecular Weight: 427.025
• Mol File: 109760-77-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: D,L-ERYTHRO-1-PHENYL-2-DECANOYLAMINO-3-MORPHOLINO-1-PROPANOL HCL(CAS DataBase Reference)
• NIST Chemistry Reference: D,L-ERYTHRO-1-PHENYL-2-DECANOYLAMINO-3-MORPHOLINO-1-PROPANOL HCL(109760-77-2)
• EPA Substance Registry System: D,L-ERYTHRO-1-PHENYL-2-DECANOYLAMINO-3-MORPHOLINO-1-PROPANOL HCL(109760-77-2)

Safety Data

• Hazardous Substances Data: 109760-77-2(Hazardous Substances Data)

Usage

Description

D,L-ERYTHRO-1-PHENYL-2-DECANOYLAMINO-3-MORPHOLINO-1-PROPANOL HCL, commonly known as EDMP, is a synthetic chemical compound with potential applications in medical research and therapeutics. As a sphingosine kinase inhibitor, it modulates the activity of enzymes involved in cell signaling pathways, making it a promising candidate for the treatment of various conditions.

Uses

Used in Pharmaceutical Industry:
EDMP is used as a research compound for studying its potential in treating conditions such as cancer, inflammation, and cardiovascular disease. Its unique structure and activity as a sphingosine kinase inhibitor make it a valuable tool for further research and development in the pharmaceutical industry.

Upstream product

• 1956-09-8 4-nitrophenyl decanoate 
• 218766-23-5 (1R,2R)-2-amino-3-(N-morpholino)-1-phenylpropan-1-ol 
• 112-13-0 n-decanoyl chloride 
• 182370-59-8 (R)-phenyl-((R)-1-((S)-1-phenylethyl)aziridin-2-yl)methanol 
• 312732-57-3 2(R)-N-[(S)-α-methylbenzyl]amino-3-morpholino-1(R)-phenylpropanol 
• 127870-56-8 (4R,5R)-4-Hydroxymethyl-5-phenyl-oxazolidin-2-one 
• 218766-11-1 (1R,2R)-2-amino-3-O-(tert-butyldimethylsilyl)-1-phenylpropane-1,3-diol 
• 218766-12-2 (4R,5R)-4-[(tert-butyldimethylsilyloxy)methyl]-5-phenyloxazolidin-2-one 
• 218766-15-5 (4R,5R)-4-(morpholin-4-ylmethyl)-5-phenyloxazolidin-2-one 
• 218766-10-0 (1R,2R)-2-(Benzhydrylidene-amino)-3-(tert-butyl-dimethyl-silanyloxy)-1-phenyl-propan-1-ol 
• 218766-13-3 (4R,5R)-(+)-4-(4'-p-toluenesulfonyloxymethyl)-5-phenyloxazolidin-2-one 
• 1236068-31-7 (2R,3R)-4-(1-tert-butoxycarbonyl-3-phenylaziridine-2-ylmethyl)morpholine 
• 1236068-33-9 (1S,2R)-1-phenyl-2-tert-butoxycarbonylamino-3-(N-morpholino)-1-bromopropane 
• 1353580-54-7 (2'S,3'S)-4-(3'-phenyloxiran-2'-ylmethyl)morpholine 

Relevant articles and documents

Stereoselective synthesis of enantiomerically pure D-threo-PDMP; manipulation of a core 2,3-diamino alcohol unit

The C(3)-N bond of various non-activated enantiomerically pure aziridine-2-methanols was regioselectively cleaved by nitrogen nucleophiles to provide a variety of β-aminoalanine derivatives in high yields. Copyright (C) 2000 Elsevier Science Ltd.

Methods for treating conditions modulated by lactosylceramide

The present invention includes methods for treatment and prophylaxis of conditions associated with lactosylceramide. The methods generally provide for administration to a mammal, particularly a human, of a therapeutically effective amount of a compound that increases enzymatic activity of UDPGal:GlcCerβ1→4 galactosylceramide (GalT-2). In vitro and in vivo assays for detecting compounds with therapeutic capacity to modulate GalT-2 are also provided.

Amino alcohol derivative and method for preparing the same

Amino alcohol derivatives with a primary amino group or a substituted amino group influence the synthesis of glycolipids and have antiviral, antitumor, metastasis inhibiting and neural cell growth enhancing functions. The amino alcohol derivatives are useful in preparing 2-acylamino alcohol derivatives.